Stay updated on XL184 Efficacy in Advanced Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the XL184 Efficacy in Advanced Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the XL184 Efficacy in Advanced Medullary Thyroid Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page has removed a citation regarding the study of Cabozantinib in progressive medullary thyroid cancer, which is a significant change in the core content.SummaryDifference0.3%
- Check14 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has undergone significant content removal regarding a clinical study on XL184 for thyroid cancer, including detailed descriptions of the study's purpose, inclusion and exclusion criteria, and the names of key committee members. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference16%
- Check36 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check79 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to XL184 Efficacy in Advanced Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XL184 Efficacy in Advanced Medullary Thyroid Cancer Clinical Trial page.